We also summarize the major preclinical and clinical advances in NF1-associated tumor therapy, including AAV-based gene delivery, oHSV approaches, CAR T-cell strategies, and small-molecule and pathway-targeted inhibitors (Table 1). The gene discussed is NF1; the disease is neoplasm.